Cosyntropin Injectable Suspension, 1 mg/mL ( DrugBank: Cosyntropin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 145 | West syndrome | 1 |
145. West syndrome
Clinical trials : 43 / Drugs : 52 - (DrugBank : 15) / Drug target genes : 28 - Drug target pathways : 26
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03347526 (ClinicalTrials.gov) | April 19, 2018 | 15/11/2017 | A Novel Approach to Infantile Spasms | A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabatrin Induction Therapy | Infantile Spasm | Drug: Cosyntropin Injectable Suspension, 1 mg/mL;Drug: Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin;Drug: Vigabatrin | University of Colorado, Denver | Pediatric Epilepsy Research Foundation;West Therapuetics, Inc | Suspended | 2 Months | 2 Years | All | 394 | Phase 3 | United States |